FDA Qualifies First AI Drug Development Tool for Use in MASH Clinical Trials

The U.S. Food and Drug Administration (FDA) has qualified the first artificial intelligence (AI)-based drug development tool, AIM-NASH, designed to support metabolic dysfunction-associated steatohepatitis (MASH) clinical trials by standardizing liver biopsy assessment and reducing variability in histologic scoring.

Standardizing Liver Disease Evaluation

The qualified tool, called AI-Based Histologic Measurement of NASH (AIM-NASH), utilizes advanced AI algorithms to analyze digital liver biopsy images and score key features, including steatosis, inflammation, ballooning, and fibrosis. This cloud-based system is intended to improve consistency across assessments and accelerate trial workflows, while pathologists retain final interpretation responsibility.

Catalyst for AI Integration in Drug Development

By earning qualification under the FDA’s Drug Development Tools (DDT) program, AIM-NASH can be used across multiple MASH drug programs without repeated validation, potentially shortening development timelines and reducing resource burdens. This milestone also sets a precedent for future AI-enabled tools in regulatory science and precision clinical research.